FOLH1 and prostate carcinoma: Driven by the favorable binding features and pharmacokinetics of ligands compared toavailable antibodies (low bone marrow toxicity due to faster clearance), PSMA ligands are currently the main focus for PSMA therapy in prostate cancer patients [13, 19].